Stay updated on LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.

Latest updates to the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows Revision: v3.3.2, replacing v3.3.1, indicating a minor site update with no changes to study content or the user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision: v3.3.1 has been added, replacing the previous v3.2.0 revision. This is an internal site version update and does not affect study details, content, or navigation.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved the government funding status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check43 days agoChange DetectedThe study record for NCT04887259 shows termination of the LAVA-051 trial. The note states this decision was a business decision and not due to safety concerns, and that the study did not progress to Phase 2.SummaryDifference0.4%

- Check71 days agoChange Detected- Added a government operating-status notice and current status pointers; updated version to v3.2.0. - Removed the specific condition 'B-cell chronic lymphocytic leukemia' and the older version tag v3.1.0.SummaryDifference4%

- Check79 days agoChange DetectedUpdate terminology from Plasma cell myeloma to Multiple myeloma and bump revision from v3.0.2 to v3.1.0.SummaryDifference0.2%

Stay in the know with updates to LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.